Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

Calidi Biotherapeutics received a notice from NYSE American on September 21, 2026, indicating non-compliance with continued listing standards due to stockholders' equity deficiency of less than $4.0 million. The company has until October 21, 2026, to submit a compliance plan and must regain compliance by March 21, 2028, or face delisting proceedings. The company's stock will trade with a '.BC' designation indicating below-compliance status, though trading continues unaffected.